Wen Hui used bioinformatics analysis, and in vitro and in vivo experiments to demonstrate that Nutlin-3a inhibits several characteristics of H295R cells, including proliferation, EMT, hormone production, and tumorigenesis, making Nutlin-3a an attractive drug for the treatment of CTNNB1-mutated ACC (142). Here, CTNNB1 is linked to adrenal cortex carcinoma.